Yungjin Pharm. Co., Ltd. (KRX:003520)

Market Cap	380.42B
Revenue (ttm)	158.79B
Net Income (ttm)	8.53B
Shares Out	182.89M
EPS (ttm)	53.49
PE Ratio	38.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,173
Average Volume	234,633
Open	2,080.00
Previous Close	2,080.00
Day's Range	2,080.00 - 2,120.00
52-Week Range	1,823.00 - 2,790.00
Beta	0.89
RSI	35.93
Earnings Date	n/a

About Yungjin Pharm.

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs. Yungjin Pharm. Co., Ltd. was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 574
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003520

Financial Performance

In 2012, Yungjin Pharm.'s revenue was 137.69 billion, an increase of 22.82% compared to the previous year's 112.11 billion. Earnings were 1.79 billion, a decrease of -30.48%.